(S (NP (NN Drug) (NN repurposing)) (VP (VBZ is) (NP (DT an) (JJ effective) (NN strategy)) (SBAR (S (VP (SBAR (S (VP (TO to) (VB identify) (NP (NP (JJ new) (NNS uses)) (PP (IN for) (NP (VBG existing) (NNS drugs))))))) (, ,) (S (VP (VBG providing) (NP (NP (DT the) (JJS quickest) (JJ possible) (NN transition)) (PP (IN from) (NP (NN bench))) (PP (TO to) (NP (VB bedside)))))))))) (. .))
(S (NP (NP (VBG Existing) (NNS methods)) (PP (IN for) (NP (NN drug) (NN repurposing))) (SBAR (WHNP (IN that)) (S (ADVP (RB mainly)) (VP (VB focus) (PP (IN on) (NP (JJ pre-clinical) (NN information))))))) (VP (MD may) (VP (VB exist) (NP (JJ translational) (NNS issues)) (SBAR (WHADVP (WRB when)) (S (VP (VBN applied) (PP (TO to) (NP (JJ human) (NNS beings)))))))) (. .))
(S (NP (NP (JJ Real) (NN world) (NNS data)) (PRN (-LRB- -LRB-) (NP (NNP RWD)) (-RRB- -RRB-)) (, ,) (PP (JJ such) (IN as) (NP (NP (JJ electronic) (NN health) (NNS records)) (CC and) (NP (NN insurance) (NNS claims)))) (, ,)) (VP (VBP provide) (NP (NP (NN information)) (PP (IN on) (NP (NP (JJ large) (NNS cohorts)) (PP (IN of) (NP (NNS users))) (PP (IN for) (NP (JJ many) (NNS drugs))))))) (. .))
(S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP present) (NP (NP (DT an) (ADJP (JJ efficient) (CC and) (JJ easily-customized)) (NN framework)) (PP (IN for) (S (VP (VBG generating) (CC and) (VBG testing) (NP (NP (JJ multiple) (NNS candidates)) (PP (IN for) (NP (NN drug) (VBG repurposing)))) (S (VP (VBG using) (NP (NP (DT a) (JJ retrospective) (NN analysis)) (PP (IN of) (NP (NNP RWDs))))))))))) (. .))
(S (S (VP (VBG Building) (PP (IN upon) (NP (JJ well-established) (NN causal) (NN inference) (CC and) (JJ deep) (NN learning) (NNS methods))))) (, ,) (NP (PRP$ our) (NN framework)) (VP (VBZ emulates) (NP (NP (JJ randomized) (JJ clinical) (NNS trials)) (PP (IN for) (NP (NP (NNS drugs)) (ADJP (JJ present) (PP (IN in) (NP (DT a) (JJ large-scale) (JJ medical) (NNS claims) (NN database)))))))) (. .))
(S (NP (PRP We)) (VP (VBP demonstrate) (NP (PRP$ our) (NN framework)) (PP (IN in) (NP (NP (DT a) (NN case) (NN study)) (PP (IN of) (NP (NP (JJ coronary) (NN artery) (NN disease)) (PRN (-LRB- -LRB-) (NP (NNP CAD)) (-RRB- -RRB-)))))) (PP (IN by) (S (VP (VBG evaluating) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (CD 55) (VBG repurposing) (NN drug) (NNS candidates))) (PP (IN on) (NP (JJ various) (NN disease) (NNS outcomes)))))))) (. .))
(S (NP (PRP We)) (VP (VBP achieve) (NP (NP (CD 6) (NN drug) (NNS candidates)) (SBAR (WHNP (WDT that)) (S (VP (VP (ADVP (RB significantly)) (VB improve) (NP (DT the) (NNP CAD) (NNS outcomes))) (CC but) (VP (RB not) (VP (VB have) (VP (VBN been) (VP (VBN indicated) (PP (IN for) (S (VP (VBG treating) (NP (NNP CAD))))))))))))) (, ,) (S (VP (VBG paving) (NP (NP (DT the) (NN way)) (PP (IN for) (NP (NN drug) (NN repurposing))))))) (. .))
